CN103483187B - 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application - Google Patents
4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application Download PDFInfo
- Publication number
- CN103483187B CN103483187B CN201310390817.XA CN201310390817A CN103483187B CN 103483187 B CN103483187 B CN 103483187B CN 201310390817 A CN201310390817 A CN 201310390817A CN 103483187 B CN103483187 B CN 103483187B
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- hydroxyl
- ethyoxyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 16
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 229960002949 fluorouracil Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000019065 cervical carcinoma Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 201000000498 stomach carcinoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 79
- 210000004027 cell Anatomy 0.000 abstract description 41
- 201000011510 cancer Diseases 0.000 abstract description 28
- 230000001093 anti-cancer Effects 0.000 abstract description 14
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 11
- 230000037396 body weight Effects 0.000 abstract description 11
- 230000006907 apoptotic process Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 210000001835 viscera Anatomy 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 230000017074 necrotic cell death Effects 0.000 abstract description 3
- HCJMNOSIAGSZBM-UHFFFAOYSA-N 6-methylsalicylic acid Chemical class CC1=CC=CC(O)=C1C(O)=O HCJMNOSIAGSZBM-UHFFFAOYSA-N 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 238000012360 testing method Methods 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000011275 oncology therapy Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000011729 BALB/c nude mouse Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003182 parenteral nutrition solution Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000029795 kidney development Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- -1 octadecyl methyl amine benzyl chloride quaternary ammonium salt Chemical class 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 208000027685 extreme exhaustion Diseases 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- AMKYESDOVDKZKV-UHFFFAOYSA-N o-orsellinic acid Chemical class CC1=CC(O)=CC(O)=C1C(O)=O AMKYESDOVDKZKV-UHFFFAOYSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses and there is 4 ethyoxyl 2 hydroxyl 6 methyl benzoic acids of formula (1) structure and Pharmaceutical composition thereof and application.Kill with external equal energy conspicuousness and/or suppress the kinds of tumor cells of human and animal in this compound body, this compound and clinical antitumor agents have conspicuousness synergistic antitumor effect, and this compound or its pharmaceutically acceptable salt can be applicable to prepare anti-tumor drug, antineoplastic pharmaceutical compositions, combined with antineoplastic compositions or adjunct antineoplastic health products.This compound energy conspicuousness promotes cancer cell-apoptosis and necrosis, regulation growth of cancer cells cycle, inhibition cancer cell propagation.The body weight of mouse, under effective antitumor dosage, is increased and internal organs is grown without conspicuousness toxicity, or toxic action conspicuousness is less than clinical anti-cancer medicine such as endoxan and 5 fluorouracils by this compound.
Description
Technical field
The invention belongs to chemical medicine, particularly relate to a kind of 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and
Pharmaceutical composition and application.
Background technology
Cancer is a major disease of serious threat human health and life security, has the most become first of the mankind
The cause of the death.According to whole world cancer statistical report, global new cancer cases in 2008 is 1266.1 ten thousand examples, dead 756.4 ten thousand examples;China
Cancer new cases are 281.6 ten thousand examples, dead 195.8 ten thousand examples." 2012 China's tumour registration annual report " discloses, and Chinese 2012 new
Sending out cases of cancer 3,120,000, average minute clock has 6 people to be diagnosed as malignant tumour.The incidence of disease of cancer is also rising, and cancer becomes
Serious threat people's health and a Major health problem of life security.
Cancer is still a kind of obstinate disease the most at present.The chemotherapy of cancer is arranged as systemic treatment
Execute, the treatment of cancer occupies epochmaking status, be also the hope the most thoroughly solving treatment of cancer problem.
The most currently used cancer chemotherapeutic drug, a lot of medicines exist that toxic and side effect is big, uncertain therapeutic efficacy is fixed, selectivity
Difference and the problem such as cancer cell resistance, make the application clinically of cancer chemotherapy drug therapy and effect be very limited.Cause
This, exploitation clear curative effect, safety low-poison, particularly there is the chemotherapeutics of selective antitumaous effect, be that PTS is studied
One important directions and urgent task.
Summary of the invention
Based on this, it is an object of the invention to provide a kind of 4-ethyoxyl-2-hydroxyl-6-methylbenzene with antitumor action
Formic acid.
Concrete technical scheme is as follows:
There is the 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid (4-ethoxy-2-hydroxy-6-of formula (1) structure
Methylbenzoic acid) or pharmaceutically acceptable salt,
It is a further object of the present invention to provide a kind of antitumor medicine composition.
Concrete technical scheme is as follows:
A kind of antitumor medicine composition, its active component includes above-mentioned 4-ethyoxyl-2-hydroxyl-6-methylbenzene first
Acid or its pharmaceutically acceptable salt.
Wherein in some embodiments, the formulation of this pharmaceutical composition is: parenteral solution, powder-injection, tablet, oral liquid, glue
Capsule, granule or electuary.
It is a further object of the present invention to provide a kind of associating antitumor medicine composition.
Concrete technical scheme is as follows:
A kind of associating antitumor medicine composition, its active component includes above-mentioned 4-ethyoxyl-2-hydroxyl-6-methylbenzene
At least one in formic acid or its pharmaceutically acceptable salt, and 5 FU 5 fluorouracil, taxol, cis-platinum or endoxan.
It is a further object of the present invention to provide the application of above-mentioned 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid.
Concrete technical scheme is as follows:
Above-mentioned 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its pharmaceutically acceptable salt are preparing antineoplastic
In application.
Wherein in some embodiments, described tumour is any one in following human tumor: human breast carcinoma, prostate
Cancer, lung cancer, cancer of the stomach, cervical carcinoma, colon cancer, liver cancer, oophoroma, leukaemia, neuroma, sarcoma.
It is a further object of the present invention to provide above-mentioned 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid to protect at adjunct antineoplastic
Application in strong product.
Concrete technical scheme is as follows:
Above-mentioned 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its pharmaceutically acceptable salt keep healthy at adjunct antineoplastic
Application in product.
A kind of adjunct antineoplastic health products, its active component include above-mentioned 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or
Its pharmaceutically acceptable salt.The formulation of these adjunct antineoplastic health products is: tablet, oral liquid, capsule, granule or electuary.
Advantages of the present invention is as follows:
4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid (4-ethoxy-2-hydroxy-6-methylbenzoic of the present invention
Acid) compound is new construction material, can carry out chemical synthesis by phase-transfer-catalyzed reactions;This compound or its salt class can
As antitumor chemotherapeutic agent, or the antineoplastic pharmaceutical compositions as antitumor activity composition, and as auxiliary
Help anti-tumor health care product.4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid is external conspicuousness can be killed and/or suppress the mankind and moves
The multiple cancer cell of thing, such as human breast carcinoma, prostate cancer, lung cancer, cancer of the stomach, cervical carcinoma, colon cancer, HCC, and mouse
Sarcoma, liver cancer, lung carcinoma cell etc..To balb/c nude mice model Human Lung Cancer and human liver cancer in this compound body, and Kunming
Murine sarcoma that kind of mouse and ICR mouse are transplanted and rat liver cancer, the tumour such as the mice lung cancer that C57BL/6J mouse is transplanted, all have
There is the growth inhibition effect of conspicuousness.This compound and the antineoplastic chemotherapy medicine of Clinical practice in vitro and/or internal all have
There is combination and cooperation antitumor action.This compound has selective antitumaous effect, and the sensitiveness of different carcinoma cell line is different, liver cancer
Cell is very sensitive to this compound.This compound energy conspicuousness promotes cancer cell-apoptosis, regulation Cancer Cell cycle and differentiation, presses down
The propagation of cancer cell processed.The body weight of mouse, under effective antitumor dosage, is increased and internal organs is grown without conspicuousness poison by this compound
Property, or toxic action conspicuousness is less than clinical anti-cancer medicine such as cyclophosphamide and 5-fluorouracil.
Accompanying drawing explanation
Fig. 1 is the mass spectrogram of formula (1) compound;
Fig. 2 is the nucleus magnetic hydrogen spectrum figure of formula (1) compound;
Fig. 3 is nuclear-magnetism carbon spectrogram and the DEPT spectrogram of formula (1) compound;
Fig. 4 is formula (1) compound dose-effect curve figure to different tumor cell lines;
Fig. 5 is time m-effect, the dose-effect relationship curve map of formula (1) Compound ira vitro anti-tumor experiment;
When Fig. 6 is antitumor (NCI-H460) test in formula (1) compound body, the tumour of different time points is relative
Volume (RTV);
When Fig. 7 is antitumor (NCI-H460) test in formula (1) compound body, the tumour of different time points is relative
Appreciation rate (%);
Fig. 8 is the NCI-H460 tumor weight that formula (1) compound is administered after 10 times;
When Fig. 9 is antitumor (QGY-7703) test in formula (1) compound body, the tumour of different time points is relative
Volume (RTV);
When Figure 10 is antitumor (QGY-7703) test in formula (1) compound body, the tumour phase of different time points
To the rate of increase (%);
Figure 11 is in formula (1) compound body at the end of antitumor (QGY-7703) experiment, and the tumour of each group is average
Weight;
Figure 12 is in formula (1) compound body at the end of antitumor (QGY-7703) experiment, the tumour of each treated animal
Photo;
Figure 13 is in formula (1) compound body at the end of antitumor (QGY-7703) experiment, the spleen of each treated animal
Photo;
Figure 14 is the flow cytomery result (QGY-7703) of formula (1) compound solvent comparison;
Figure 15 is the flow cytomery result (QGY-7703) of formula (1) compound;
Figure 16 is formula (1) compound (D4,50 μMs) the Western Blot testing result at QGY-7703;
Figure 17 is formula (1) compound (D1,200 μMs) the Western Blot testing result at HCT-116;
Figure 18 is formula (1) compound (D2,150 μM) the Western Blot testing result at MCF-7;
Figure 19 is formula (1) compound (D1,200 μM) the Western Blot testing result at A-549;
Figure 20 is that formula (1) compound combines anti-A-549 function of tumor with the external of 5 FU 5 fluorouracil;
Figure 21 is that formula (1) compound combines anti-A-549 function of tumor with the external of cis-platinum.
Detailed description of the invention
The present invention is further elaborated by the following examples.
The embodiment 1 :-2-hydroxyl-6-methyl benzoic acid (4-ethoxy-2-of compound 4-ethyoxyl shown in formula (1)
Hydroxy-6-methylbenzoic acid) synthesis and Structural Identification
1, preparation method
Phase-transfer Wittig reaction and column chromatography for separation
Utilize phase-transfer-catalyzed reactions, in the presence of NaOH, 2,4-dihydroxy-6-methyl benzoic acids and sulfuric acid diethyl
Ester (mol ratio is 0.2:0.18), at the double octadecyl methyl amine benzyl chloride quaternary ammonium salt of catalyst HA-1() under effect in 60-65
DEG C reaction 3h.After completion of the reaction, it is cooled to 25 DEG C, pours in frozen water, adjust pH value to neutral with watery hydrochloric acid, separate organic layer;Water
Layer toluene extracts 2 times, merges organic layer;Washing organic layer 3 times, anhydrous sodium sulfate is dried.Decompression boils off solvent toluene, product
Use silica gel column chromatography technology to carry out again isolated and purified, obtain compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid.
2, Structural Identification
The mass spectrogram (as shown in Figure 1) of compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid;
The nucleus magnetic hydrogen spectrum figure (as shown in Figure 2) of compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid;
The nuclear-magnetism carbon spectrogram of compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and DEPT spectrogram (as shown in Figure 3).
Embodiment 2: the biological experiment result of formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid
Formula (1) the compound 4-ethyoxyl-2-hydroxyl-6-first of the present invention is described below by part specific experiment illustration
Yl benzoic acid (following chart represents with D6B2 or D, lower same;D1 is 200 μMs, D2 is 150 μMs, D3 is 100 μMs, D4 is 50 μMs,
D5 is 25 μMs) there is conspicuousness and selective antitumor action and the synergistic antitumor effect of clinical antitumor agents, Yi Jiqi
Toxicological safety, Antitumor Mechanism.
1, the anti-cancer effect in vitro of 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid:
Test method: formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid dissolves with DMSO, by ultimate density
It is 25,50,100,150,200 μMs and carries out external anticancer test.Collect the exponential phase mankind or animal tumor cell, with completely
After culture medium suspendible, being inoculated in 6 orifice plates, every hole adds 2ml cell suspension.37℃、5%CO2After incubator is cultivated 24 hours, take 3
Porocyte counts the cell number as 0 hour;Suck the nutrient solution in remaining hole, be then separately added into containing respective concentration by design
The complete culture solution 2ml of formula (1) compound, sets DMSO solvent control simultaneously.It is parallel, carefully that every concentration and DMSO control group do 9 holes
Born of the same parents after dosing in 37 DEG C, 5%CO2Incubator continues to cultivate.24h, 48h, 72h after dosing, it is thin that every concentration collects 3 holes respectively
Born of the same parents count, and calculate mean value and the standard deviation of cell number, draw cell growth curve, carry out significant difference inspection.With
Shi Caiyong 96 orifice plate is cultivated, and measures the OD value after drug-treated 24,48 and 72 hours, the time m-effect of observation medicine with mtt assay
Relation.
Result: formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid is to MCF-7 cell strainHJ2mm, people
It is anticancer that lung cancer cell line A-549, human colon cancer cell strain HCT-116, human hepatoma cell strain QGY-7703 etc. are respectively provided with conspicuousness
Effect.This compound has significant difference to the inhibiting rate of different carcinoma cell, and human hepatocarcinoma cells QGY-7703 is to this compound
Very sensitive.200 μMs of concentration, 72 hours, the inhibiting rate of QGY-7703, MCF-7, A-549 and HCT-116 is divided by this compound
It is not 95.07%, 78.26%, 50.39% and 51.84%, there is obvious dose-response relationship, its half-inhibition concentration (IC50)
It is respectively 70 μMs, 135 μMs, 190 μMs and 200 μMs.The external anti-cancer result of 72 hours is shown in Fig. 4.Sieve at other Anticancer Activity in vitro
In choosing test, formula (1) compound treatment cancer cell, after 72 hours, is shown under the microscope to human cervical carcinoma cell Hela, people's cancer of the stomach
Cell SGC-7901, Human Prostate Cancer Cells PC-3, Proliferation of Human Ovarian Cell SKOV-3, human leukemia cell K-562 and HL-60,
Human glioma cell U-251 etc. has the external suppression of conspicuousness or these cell lines (are not entered by killing action at present temporarily
Row dose-effect relationship and time m-effect relation research).
This compound dose-effect relationship figure to human liver cancer cell QGY-7703 anti-cancer effect in vitro at different dosages
With time m-effect relation figure (mtt assay) see Fig. 5.
2,4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid mankind's maxicell lung cancer NCI-to balb/c nude mice model
The internal antitumaous effect of H460
Test method: male balb/c nude mice (body weight 16~18g), every right side dorsal sc inoculation mankind's maxicell lung
Cancer NCI-H460 cell suspension 0.1ml(5 × 107Cells/ml).Inoculation cancer cell after the 12nd day, major part mouse subcutaneous go out
Existing naked eyes visual tumors.With vernier caliper measurement, the gross tumor volume that calculates every mouse.Tumor-bearing mice is pressed gross tumor volume size
It is randomly divided into DMSO control group and formula (1) compound administration group, often 8 tumor-bearing mices of group.Formula (1) compound is with aseptic mass spectrum
Pure DMSO prepares, and dosage is 30mg/kg;Control group mice gives the DMSO of equal volume.Mouse from packet after second
It starts intraperitoneal injection, is administered once every other day, within every 4 days, measures 1 gross tumor volume and body weight, calculate tumour relative volume,
The relative appreciation rate of tumour.After being administered 10 times, put to death mouse, completely strip tumour, liver,spleen,kidney and testis, measure tumor weight
And each organ weights, calculate tumor weight inhibiting rate and each organ coefficient.
Result: the suppression result of NCI-H460 tumour is shown in Fig. 6, Fig. 7, figure by 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid
8.The growth (p < 0.05) of 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid energy conspicuousness suppression Human Lung Cancer NCI-H460, test
At the end of, the weight inhibiting rate of tumour is 43.51%, and the relative appreciation rate of tumour is 51.96%, the tumor weight of administration group, swollen
Knurl relative volume compares with negative control group (representing with NC, lower same), declines (p < 0.05) in conspicuousness.
3,4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid is to transplantability human liver cancer QGY-7703 anticancer in nude mouse
Effect
Test method: to raising the female balb/c nude mice (body weight 16~18g) of 1 week through adaptability, carries on the back on right side for every
Portion's subcutaneous vaccination QGY-7703 cell suspension 0.1ml(1 × 108Cells/ml).Nude mice is raised in SPF laboratory.Inoculation cancer is thin
After born of the same parents the 21st day, mouse is subcutaneous there is naked eyes visual tumors.With major diameter and the transverse diameter of vernier caliper measurement mouse tumor, calculate
Gross tumor volume.Tumor-bearing mice is randomly divided into DMSO solvent control group, 5 FU 5 fluorouracil (5-Fu) sun according to gross tumor volume size
Property drug control group and formula (1) compound administration group, often organize totally 6 tumor-bearing mices.4-ethyoxyl-2-hydroxyl-6-methylbenzene first
After acid is dissolved with the aseptic pure DMSO of mass spectrum, then diluting with the aseptic PBS of equal-volume, dosage is 20mg/kg;Solvent control group
Mouse gives the DMSO/PBS(1:1 of equal volume);5-Fu dilutes with equal-volume DMSO, and 5-Fu dosage is 30mg/kg.Little
The mouse second day beginning intraperitoneal injection after packet, is administered once every other day, within every 4 days, measures 1 gross tumor volume and body weight.Give
After medicine 12 times, put to death mouse, completely strip tumour, liver,spleen,kidney, measure tumor weight, Mouse Weight and each organ weights.
Result: formula (1) the compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid suppression result to QGY-7703 tumour
See Fig. 9, Figure 10, Figure 11.The growth (p < 0.05) of formula (1) compound energy conspicuousness suppression human liver cancer QGY-7703, test knot
Shu Shi, the weight inhibiting rate of tumour is 69.83%, and the relative appreciation rate of tumour is 30.84%, the tumor weight of administration group, tumour
Relative volume compares with control group, declines (p < 0.05) in conspicuousness.This compound inhibitory action conspicuousness to human liver cancer
It is better than the inhibitory action to lung cancer.At the end of experiment, Figure 12 is shown in by the QGY-7703 tumour photo of each group.
Murine sarcoma S-180 that Kunming mouse and ICR mouse are transplanted by 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid,
Rat liver cancer H-22, and C57BL/6J mouse transplant mice lung cancer 3ll be respectively provided with conspicuousness internal antitumaous effect (p <
, and there is dose-effect relationship 0.05).
4, the 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid toxic action to nude mice
Experimental technique: in nude mouse in anticancer test, is measuring each time point of gross tumor volume, is measuring the body of mouse simultaneously
Weight;When off-test, put to death mouse, completely take out mouse liver, spleen, kidney, testis (male mouse) and weigh, calculating each dirty
Device coefficient.
(1) impact that male mouse body weight and internal organs are grown
The body weight (g) of table 1. male balb/c mouse different time points
*: P < 0.05
Result: after being administered 4 times, Mouse Weight is increased by formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid
Present inhibitory action.
The organ coefficient of table 2. male balb/c mouse
*:P<0.05
Result: formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid can affect liver and the spleen of male nude mouse
Dirty growth, but do not affect kidney and the testicualr development of male mice.
(2) impact that, body weight dead on female mice and internal organs are grown
The body weight (g) of table 3. female balb/c mouse different time points
2 mouse of #:5-fluorouracil group are dead at the 20th day, separately have 3 extremes to become thin, dying;
*: from the beginning of the 8th day, 5 FU 5 fluorouracil and D6B2 group body weight conspicuousness are less than solvent control group, P < 0.05;
Result: cancer therapy drug 5 FU 5 fluorouracil and formula (1) compound energy conspicuousness affect Mouse Weight and grow, 5-fluorine urine is phonetic
Pyridine affects conspicuousness higher than this compound to Mouse Weight.At the 20th day of experiment, 5-Fu group had 2 animals dead because of exhaustion,
Separately there are 3 mouse extreme exhaustions and dying.Formula (1) compound treated animal is still bouncing, nothing death when off-test.
The organ coefficient of table 4. female balb/c mouse
*: P < 0.05
Result: 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid can affect female mice kidney development, and 5 FU 5 fluorouracil
Energy conspicuousness affects spleen and the kidney development (Figure 13 is shown in by the spleen photo of each group mouse) of mouse.This compound is to Mouse Weight
It is less than cancer therapy drug 5 FU 5 fluorouracil with the development impact conspicuousness of internal organs.
5,4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid is on apoptosis of tumor cells and the impact of cell cycle:
Experimental technique: HCC QGY-7703, after formula (1) compound treatment 48h, uses flow cytometer (FACS)
Detection cell cycle and Apoptosis situation.Result is shown in Figure 14 and Figure 15.
Result: formula (1) compound energy conspicuousness promotes apoptosis and the necrosis of cancer cell, and drug-treated group is 100 μ at dosage
When M, 150 μMs and 200 μMs, the DNA fragment peak (P2) that Apoptosis and necrosis is formed is respectively 13.5%, 24.7% and 32.7%, has
Significantly dose-effect relationship, conspicuousness is higher than the 6.8% of control group, and this compound conspicuousness postpones the G0/ of cancer cell
G1 and G2/M peak value and cell cycle distribution ratio, hence it is evident that affect differentiation and the cycle of cancer cell.
6,4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid to Apoptosis marker protein Cleaved Caspase-3 and
The impact that Cleaved PARP level and PTEN Tumor Suppressor Gene are expressed:
Experimental technique: HCC QGY-7703, colon cancer cell HCT-116, breast cancer cell MCF-7, lung carcinoma cell
A-549, after formula (1) compound treatment 24 hours, collects cell, cracks, adjusts protein concentration, use Western Blot skill
Art measures.Result is shown in that (SP represents positive control Staurosporine, and SP1 is 50nM, SP2 for Figure 16, Figure 17, Figure 18, Figure 19
For 100nM).
Result: 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid energy conspicuousness promotes HCC QGY-7703, colon cancer
The formation of Apoptosis mark primer Cleaved PARP in cell HCT-116, to breast cancer cell MCF-7, lung carcinoma cell A-
In 549, the formation of Cleaved PARP is without effect.This compound nor affect on cancer cell Cleaved Caspase-3 level and
The expression of PTEN.
7,4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and the synergistic antitumor effect of other cancer therapy drug:
In vitro in anticancer test, compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid is phonetic with cancer therapy drug 5-fluorine urine
Pyridine, taxol and cis-platinum have the external synergistic antitumor effect of conspicuousness.The results are shown in Table 5, table 6 and Figure 20, Figure 21.
Test method: in external anticancer test, arranges negative control group, the positive cancer therapy drug group of a dosage, 3 agent
The D6B2 group of amount and the D6B2 of three dosage add positive cancer therapy drug group, within 72 hours after dosing, collect cell count, and calculating presses down
Rate processed and carry out statistical analysis.
Table 5.D6B2 combines the 5-Fu In-vitro Inhibitory Effect (n=3, x ± s) to people's lung cancer cell A-549
Compare with control group,*P < 0.05,**P < 0.01;Compare with 5-FU,△P < 0.05,△△P < 0.01.
Table 6D6B2 combination with cisplatin (DDP) to the inhibitory action of lung cancer cell A-549 (n=3,)
Compare with control group,*P < 0.05,**P < 0.01;Compare with DDP,△P < 0.05,△△P < 0.01.
Taxol is when 1nM concentration, and the external inhibiting rate to MCF-7 is 28.85%, and D6B2 is when concentration is 100 μMs pair
The inhibiting rate of MCF-7 is 15.38%, and during the two synergy, the inhibiting rate to MCF-7 is 52.16%, 4-ethyoxyl-2-hydroxyl-
6-methyl benzoic acid and taxol have conspicuousness combination and cooperation anti-cancer effect in vitro in vitro to human breast cancer cell line Bcap-37.
In vivo in anticancer test, 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid has in vivo with endoxan combines
Suppression rat liver cancer H-22.Endoxan is when 40mg/kg, and the inhibiting rate to rat liver cancer H-22 is 75.83%, and D6B2 exists
During 40mg/kg, the inhibiting rate to H-22 is 38.99%, when the two is used in combination, combines group mouse and there are no tumor growth.
Embodiment 3:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid is neutralized in a heated condition with sodium acid carbonate
Reaction, then adjusts pH value to 7.0-7.5 with soda ash solution, heats, evaporates, crystallizes the sodium salt of the formula that i.e. formed (1) compound
Sodium4-ethoxy-2-hydroxy-6-methylbenzoate, can be dissolved in water.Formula (1) compound also can be with other alkalescence
Ion or group form salt.
Embodiment 4:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid, dissolves with a small amount of DMSO, injects use routinely
Water, essence filter, parenteral solution is made in embedding sterilizing.
Embodiment 5:
The sodium salt Sodium4-ethoxy-2-hydroxy-6-methylbenzoate of formula (1) compound, fills routinely
Penetrating and dissolve with water, essence filter, parenteral solution is made in embedding sterilizing.
Embodiment 6:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, with a small amount of ethanol, methyl alcohol or distillation
After water dissolves, filter with aseptic suction funnel, more aseptic essence filter, it being sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains
Powder-injection.
Embodiment 7:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, the ratio needed in preparation adds
Excipient, makes pulvis.
Embodiment 8:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, the ratio needed in preparation adds
Excipient, pelletizing press sheet makes tablet.
Embodiment 9:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, oral liquid preparation method is made routinely
Oral liquid.
Embodiment 10:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, the ratio needed in preparation adds
Excipient, makes capsule or granule or electuary.
Embodiment 11:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, added in the ratio of product needed
Food or other carrier, make health products or other functional articles.
Embodiment 12:
Formula (1) compound 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its esters, needed by treatment, anti-swollen with other
Tumor medicine mixes in proportion, makes various preparation, forms combined with antineoplastic compositions.
Embodiment described above only part have expressed the several embodiments of the present invention, and it describes more concrete and detailed,
But therefore can not be interpreted as the restriction to the scope of the claims of the present invention.It should be pointed out that, for the ordinary skill of this area
For personnel, without departing from the inventive concept of the premise, it is also possible to make some deformation and improvement, these broadly fall into the present invention
Protection domain.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (4)
1. an associating antitumor medicine composition, it is characterised in that its active component includes the 4-second with formula (1) structure
Epoxide-2-hydroxyl-6-methyl benzoic acid or its pharmaceutically acceptable salt, and 5 FU 5 fluorouracil, taxol, cis-platinum or ring phosphinylidyne
At least one in amine,
2. 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid or its pharmaceutically acceptable salt with formula (1) structure are anti-in preparation
Application in tumour medicine,
Application the most according to claim 2, it is characterised in that described tumour is any one in following human tumor: people
Breast cancer, prostate cancer, lung cancer, cancer of the stomach, cervical carcinoma, colon cancer, liver cancer, oophoroma, leukaemia, neuroma, sarcoma.
4. have the 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid of formula (1) structure or its pharmaceutically acceptable salt prepare auxiliary
Help the application in anti-tumor health care product,
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310390817.XA CN103483187B (en) | 2013-08-30 | 2013-08-30 | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application |
PCT/CN2014/000808 WO2015027669A2 (en) | 2013-08-30 | 2014-08-29 | Phenyl-substituted compound, pharmaceutical composition and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310390817.XA CN103483187B (en) | 2013-08-30 | 2013-08-30 | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103483187A CN103483187A (en) | 2014-01-01 |
CN103483187B true CN103483187B (en) | 2016-08-24 |
Family
ID=49823844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310390817.XA Expired - Fee Related CN103483187B (en) | 2013-08-30 | 2013-08-30 | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103483187B (en) |
WO (1) | WO2015027669A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103483187B (en) * | 2013-08-30 | 2016-08-24 | 香港科技大学 | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application |
CN114948927B (en) * | 2021-02-20 | 2024-10-15 | 无锡九基生物科技有限公司 | Application of 3-benzofuranone derivative containing benzylidene in preparation of antitumor drugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103102264A (en) * | 2013-01-07 | 2013-05-15 | 四川大学 | Preparation method of salicylic acid compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6434913A (en) * | 1987-07-31 | 1989-02-06 | Mitsubishi Chem Ind | Antitumor agent |
CN103483187B (en) * | 2013-08-30 | 2016-08-24 | 香港科技大学 | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application |
-
2013
- 2013-08-30 CN CN201310390817.XA patent/CN103483187B/en not_active Expired - Fee Related
-
2014
- 2014-08-29 WO PCT/CN2014/000808 patent/WO2015027669A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103102264A (en) * | 2013-01-07 | 2013-05-15 | 四川大学 | Preparation method of salicylic acid compound |
Also Published As
Publication number | Publication date |
---|---|
WO2015027669A2 (en) | 2015-03-05 |
CN103483187A (en) | 2014-01-01 |
WO2015027669A3 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102432663B (en) | Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine | |
CN109464460A (en) | A kind of pharmaceutical composition and its application in preparation of anti-tumor drugs improving anti-tumor drug sensibility | |
CN106749089A (en) | The preparation of new fluoro thiazole hydrazone compounds and its application in antineoplastic | |
CN103483187B (en) | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application | |
CN102614170A (en) | Application of artemisinin B in preparation of antitumor drugs | |
CN104586873B (en) | Application of the oroxin A in treating cancer medicine is prepared | |
CN101940569B (en) | Medicament composition containing sorafenib, artemisinin and artemisinin derivative and application thereof in preparing medicament for treating cancer | |
CN100357264C (en) | Charles ketone oxime and its composition , preparation method and uses | |
CN102688489B (en) | Pharmaceutical composition containing triptolide, triptolide derivative and Bc1-2 inhibitor and application thereof | |
WO2008148269A1 (en) | Anti-tumor medicine containing betulinic acid derivatives | |
CN102188557A (en) | Application of Juncus effuses L. extract in preparing anti-tumor or angiogenesis-inhibiting medicament, health food or cosmetic | |
CN103893168A (en) | Application of isopimpinellin in preparation of antitumor drugs and anticancer reversal agents | |
CN107286123B (en) | Preparation method and application of diphenyl furan compound | |
CN109453176A (en) | A kind of anti-tumor compositions and its preparing antitumor or the application in terms of inhibiting cancer cell drug, anti-tumor drug | |
CN109481454A (en) | Anti-tumor compositions and its application in terms of preparing antitumor or inhibition cancer cell drug, anti-tumor drug | |
CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
CN104892707B (en) | A kind of controlled syntheses compound CLCN and its application in medicines resistant to liver cancer | |
CN101289453B (en) | Ellagic acid compounds preparation method | |
CN102423307A (en) | Application of dehydroeffusol in preparation of drugs for tumor preventing and tumor angiogenesis inhibiting, health food or cosmetics | |
CN102702215B (en) | Compound mangostenone F, preparation method and application in preparation of antitumor drugs thereof | |
CN101233125A (en) | Antitumoral compounds | |
CN102440987B (en) | Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof | |
CN103351383A (en) | 5-fluorouracil nitroxyl-free-radical anti-tumor drug | |
CN103833766B (en) | Shore, Agra dimethylamine fumarate and the purposes in prepared by medicine thereof | |
CN103980174B (en) | Substituted pyrrolidin dithiocarbamic acid bismuth (III) title complex and preparation method thereof and preparing the application in antitumor drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20180830 |